Hemab doses first patient with candidate for rare blood disease
The biotech company, which uses technology from Novo Nordisk and Genmab, is expecting the first data from an early-stage study to arrive in H2 2023.
by albert rønning-andersson, translated by daniel pedersen
Hemab Therapeutics has passed a big milestone. At the annual JPMorgan Healthcare Conference in San Francisco, the biotech company announced it had dosed the first patient in a phase I/II trial of HMB-001, a treatment candidate for rare bleeding disorder Glanzmann thrombasthenia.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Holdings invests in newly merged blood disease company
For subscribers
Pfizer hemophilia therapy hits goal in final-stage study
For subscribers
